According to the recent research report titled ‘Global Glioblastoma Multiforme Treatment Market Size study, by Treatment (Surgery Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Fields Therapy, Immunotherapy), by Drug class (Temozolomide, Bevacizumab, Lomustine, Carmustine Wafers, Others), by End use (Hospitals, Clinics, Ambulatory Surgical Centres), and Regional Forecasts 2021-2027’, available with MarketStudyReport, global glioblastoma multiforme treatment market was valued at USD 2.14 billion in 2020 and is expected to expand at a CAGR of 8.6% over 2021-2027, subsequently reaching USD 3.81 billion by the end of the forecast period.
 

Increasing research & development, along with rising acceptance of novel therapy and combination therapy are the key factors driving worldwide glioblastoma multiforme treatment market growth.
 

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4219614/
 

For the unversed, glioblastoma multiforme (GBM) is a severe fast-growing and aggressive brain tumor. It is becoming more common with increasing incidences of brain tumors worldwide.
 

Notably, according to the National Brain Tumor Society, 700,000 individuals in the United States were diagnosed with a primary brain tumor in 2020, with an additional 85,000 people diagnosed by the end of 2021. Thus, in June 2019, the US Food and Drug Administration authorized Pfizer's Zirabev, a biosimilar for Avastin, that is used to treat colorectal cancer, recurrent glioblastoma, and NSCLC, among others.
 

In addition, the US FDA gave Denovo biopharma's DB102 (enzastaurin) fast track approval for designation to treat new patients with glioblastoma in July 2020. The increasing number of novel treatments are anticipated to contribute to market growth in the ensuing years.
 

Despite the positive outlook of global glioblastoma multiforme treatment industry, factors such as strict regulations, lack of efficient therapies for the ailment, and high cost associated with drug development are anticipated to hamper the overall remuneration scope during the stipulated timeframe.
 

Elaborating on regional terrain, North America leads the market in terms of share, due to strong government support for the development of the healthcare sector, increased awareness of rare conditions, and easy access to high-quality medical facilities.
 

Meanwhile, Asia Pacific market is expected to register a strong CAGR over 2021-2027, owing to the introduction of generic temozolomide, improving economy, increased risk among the growing elderly population, and rising investments in the healthcare sector.
 

Coming to competitive landscape, Karyopharm Therapeutics Inc., Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Arbor Pharmaceuticals LLC, Amgen Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Merck & Co. Inc. are the major firms operating in worldwide glioblastoma multiforme treatment marketplace.